Navigation Links
Chimerix, Inc. Appoints Kenneth I. Moch Chief Operating Officer
Date:7/16/2009

RESEARCH TRIANGLE PARK, N.C., July 16 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing orally available antiviral therapeutics, announced today that Kenneth I. Moch has joined the company as Chief Operating Officer.

Mr. Moch brings more than 25 years of experience in managing and financing biomedical technologies, and has played a key role in building several life science companies. In this newly-created position, Mr. Moch will be responsible for overseeing corporate and financial strategy, business development and operations, reporting to George Painter, Ph.D., Chimerix's President and Chief Executive Officer.

"Ken is a seasoned industry executive whose depth and breadth of leadership experience significantly strengthens the Chimerix management team," said Dr. Painter. "I look forward to working closely with Ken on a shared vision for advancing Chimerix's pipeline of potent broad spectrum antiviral compounds, and building an organization focused on advancing important new medicines."

"With a rich pipeline of next-generation antiviral drug candidates, productive platform technology, an extraordinary library of new leads and supportive top-tier investors, Chimerix combines deep assets with the scientific heritage necessary to emerge at the forefront of antiviral drug development," said Mr. Moch. "I am excited to join this veteran team. We have the opportunity to create much-needed new pharmaceutical products with promise in a broad range of challenging viral diseases."

Prior to joining Chimerix, Mr. Moch founded Euclidean Life Science Advisors, a provider of strategic advisory services to life sciences companies, where he most recently served as President and CEO of BioMedical Enterprises, Inc., a developer and marketer of orthopaedic memory metal implants. Previously, he was Managing Director, Healthcare Investment
'/>"/>

SOURCE Chimerix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Progenitor Cell Therapy Appoints VP of Manufacturing Operations
2. Poniard Pharmaceuticals Appoints Gary A. Lyons to Board of Directors
3. Covance Appoints Dr. Steven M. Michael as Vice President and Chief Scientific Officer of Global Bioanalytical Services
4. OncoMed Pharmaceuticals Appoints Sunil Patel Senior Vice President, Corporate Development
5. Rib-X Pharmaceuticals, Inc. Appoints Dr. Russell Greig to Board of Directors
6. BioStorage Technologies, Inc., Appoints Jeff Goddard to Global Head of Sales
7. Sundia MediTech Appoints Dr. Tong Xu as VP of Process Chemistry
8. Novavax Appoints Stanley Erck to Board of Directors
9. Qforma Appoints Four Executives in Sales and Field Operations
10. WuXi PharmaTech Appoints Felix Hsu as Senior Vice President of U.S. Operations
11. WuXi PharmaTech Appoints Wei-Min Chang as Vice President of Operations and General Manager of SynTheAll Manufacturing Facility, Eric Gu as Vice President of Business Development for Manufacturing Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... Immunovaccine Inc. (“Immunovaccine”) (TSX: IMV), ... announced that the U.S. Food and Drug Administration ... and Phase I clinical trials of the DPX-Anthrax ... co-development agreement signed with Gilead Life Sciences. The ... the DPX-Survivac. , “We have been in talks ...
(Date:2/27/2015)... Illinois (PRWEB) February 27, 2015 FamilyFarms ... Sims, General Manager of State Line Farms, received the ... recognizes a producer, under the age of 35, who ... "It is an honor to win the Tomorrow's Top ... discovering who won the Top Producer Award and learning ...
(Date:2/26/2015)... S&P Capital IQ (MHFI) announced today that ... MabVax Therapeutics Holdings Inc . MabVax ... company focused on the development of vaccine and antibody-based ... of cancer. MabVax has discovered a pipeline of human ... generated by patients who have been immunized against targeted ...
(Date:2/26/2015)... LEXINGTON, Mass., Feb. 26, 2015   Synageva ... a biopharmaceutical company developing therapeutic products for rare ... and provided 2015 goals, other key objectives, and ... conference call today at 4:30 p.m. EST to ... business update.  To participate in today,s call by ...
Breaking Biology Technology:Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3Matt Sims Receives the 2015 Tomorrow’s Top Producer Horizon Award 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 5Synageva BioPharma Reports 2014 Full Year Financial Results 2Synageva BioPharma Reports 2014 Full Year Financial Results 3Synageva BioPharma Reports 2014 Full Year Financial Results 4Synageva BioPharma Reports 2014 Full Year Financial Results 5Synageva BioPharma Reports 2014 Full Year Financial Results 6Synageva BioPharma Reports 2014 Full Year Financial Results 7Synageva BioPharma Reports 2014 Full Year Financial Results 8Synageva BioPharma Reports 2014 Full Year Financial Results 9
... Ahmed Fazil Madison, Wis. - The 2006 ... has launched its first identity theft product, and has ... and three million customers after two years. , ,This probably ... plans to reach positive cash flow, but consider the total ...
... of Fresno in California's San Joaquin Valley is one of ... from grapes to livestock, from almonds to dairy products, and ... San Joaquin Valley these days is biofuel. , ,Like many ... recent visit are happy that demand for ethanol and biodiesel ...
... appears that Wisconsin has failed in its bid to lure a ... a maker of neural stem cell kits for researchers, apparently has ... it was spun out of the University of Georgia . ... likely that the company will remain in Georgia, despite an incentive ...
Cached Biology Technology:Identity theft start up has fast-track growth plans 2Identity theft start up has fast-track growth plans 3Kind approach to leveraging biofuels 2Kind approach to leveraging biofuels 3Georgia stem cell company likely to stay put 2
(Date:2/18/2015)... , Feb. 18, 2015  Cepheid (NASDAQ: CPHD ... the following conferences, and invited investors to participate via webcast. ... Boston, MA Tuesday, March 3, 2015 at 11.20 ... Orlando, FL Wednesday, March 4, 2015 ... To access the live webcasts for these events, please visit ...
(Date:2/12/2015)... 2015   MedNet Solutions , a global ... management systems, has recently bolstered its ... iMedNet as the eClinical solution ... healthcare consultants.  Building on the Program,s existing benefits ... numerous co-marketing opportunities), MedNet,s new and improved program ...
(Date:2/11/2015)... February 11, 2015 ... "Access Control Market by Product (Cards and Readers, Biometrics, ... Defense, Government, Industrial, Healthcare, Education) and By Geography - Global ... MarketsandMarkets, the Access Control Market is expected ... at a CAGR of 10.6% between 2014 ...
Breaking Biology News(10 mins):Cepheid to Webcast Upcoming Financial Presentations 2MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4
... Most drug therapy interventions for people with autism have ... Now, University of Missouri researchers are examining the use ... pressure and control heart rate as well as to ... with autism difficulty with normal social skills, language ...
... release is available in German . , London. The ... 45 per cent more than previously thought. This is the conclusion ... heavy oxygen atoms in the carbon dioxide of the atmosphere driven ... dioxide were converted faster than expected during the El Nio years, ...
... drug that would treat most, if not all, autoimmune disorders, ... not be so hard to do thanks to a team ... the body to prevent unnecessary immune reactions. This molecule, pronounced ... overreacting when food passes through our bodies, and it may ...
Cached Biology News:Study finds promising drug treatment for improving language, social function in people with autism 2Productivity of land plants may be greater than previously thought 2Productivity of land plants may be greater than previously thought 3Scientists discover a 'master key' to unlock new treatments for autoimmune disorders 2
... highly purified preparation of the catalytic subunit ... recognizes the identical cleavage site as the ... activity (1). Novagen&'s enzyme is produced in ... highest activity available, and is qualified for ...
Strip Removal Tool 25/Box...
... The Beacon 2000 Fluorescence Polarization System ... research and assay development. Standard Beacon ... 2000 System uses a quartz-halogen lamp ... of 360-700 nm. It accommodates all ...
... variety of solvent vapors that can contaminate and ... (GCF400) allows for the collection of liquid into ... cooling time minimizes waiting period., , Easy ... , -50?C Temerature for ...
Biology Products: